TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: ADBIO    
Biogen Program, Alzheimer Disease Evaluation, Spinal Fluid

Useful For Suggests clinical disorders or settings where the test may be helpful

Assessment of adults with cognitive impairment being evaluated for Alzheimer disease and other causes of cognitive impairment

 

Biogen’s Amyloid Beta Confirmed Program

 

This test should not be used to predict the development of dementia or other neurologic conditions or to monitor response to therapies.

Highlights

Measurement of beta-amyloid (1-42)(Abeta42), total-Tau, and phosphorylated-Tau (p-Tau) in cerebrospinal fluid (CSF) is useful in the differential diagnosis of Alzheimer disease (AD) and other causes of cognitive impairment.

 

These assays are being proposed as an alternative/adjunct to imaging studies to assess AD pathology.

 

The p-Tau/Abeta42 ratio provides excellent concordance with amyloid positron emission tomography (PET) scan to assess the presence of amyloid deposition in patients with AD.

Method Name A short description of the method used to perform the test

Electrochemiluminescent Immunoassay (ECLIA)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Biogen Alzheimers Disease Eval, CSF

Aliases Lists additional common names for a test, as an aid in searching

ABeta
Amyloid Beta 42
Beta-Amyloid 42
Phosphorylated Tau
pTau
Total Tau
tTau